Alantra Private Equity completed the acquisition of Imegen, Genycell Biotech and Health in Code.

Alantra Private Equity completed the acquisition of Imegen, Genycell Biotech and Health in Code, three Spain-headquartered genetic diagnostic companies. Financial terms were not disclosed. "We are excited to participate as a majority shareholder in the resulting group formed by the integration of Imegen, Genycell Biotech and Health in Code, three of the most prestigious companies in the genetic diagnosis sector in Spain. This is the first time three companies in this branch of activity have merged in Spain, so the agreement is a milestone in the Iberian market. With the support of Alantra Private Equity, as well as the rest of the shareholders and the leadership of the management team, we are confident that this project will achieve high levels of national and international growth in a sector with an extremely high potential," David Santos, Alantra Private Equity Partner.